Cancer Therapy

Pharma company announces publication of study examining Talabostat

Published in Cancer Weekly, August 31st, 2004

Point Therapeutics, Inc., (NASDAQ: POTP) announced that a study investigating its lead product candidate talabostat (PT-100) has been published in the August edition of Cancer Research.

The study is entitled "PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, has Potent AntiTumor Effects and Augments Antibody-mediated Cytotoxicity via a Novel Immune Mechanism."

The preclinical study showed that talabostat slowed growth or caused regression and rejection of certain experimental tumors in mice in vivo. The authors demonstrated that the antitumor effect of talabostat appears to involve tumor-specific cytotoxic T lymphocytes (CTL) and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-08-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry